$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 14 Dec 2016 | 42350 | In Stock

Introduction

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)

- The report reviews Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics and enlists all their major and minor projects

- The report assesses Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 4

    List of Figures 4

    Introduction 5

    Global Markets Direct Report Coverage 5

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) Overview 6

    Therapeutics Development 7

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Stage of Development 7

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Therapy Area 8

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Indication 9

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Products Glance 11

    Late Stage Products 11

    Early Stage Products 12

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Products under Development by Companies 13

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Therapeutics Assessment 15

    Assessment by Monotherapy/Combination Products 15

    Assessment by Mechanism of Action 16

    Assessment by Route of Administration 17

    Assessment by Molecule Type 19

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Companies Involved in Therapeutics Development 21

    Altor BioScience Corp 21

    Cytune Pharma SAS 22

    Nektar Therapeutics 23

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Drug Profiles 24

    ALT-803 - Drug Profile 24

    Product Description 24

    Mechanism Of Action 24

    R&D Progress 24

    CYP-0150 - Drug Profile 27

    Product Description 27

    Mechanism Of Action 27

    R&D Progress 27

    Monoclonal Antibody Conjugates for Infectious Disease and Oncology - Drug Profile 28

    Product Description 28

    Mechanism Of Action 28

    R&D Progress 28

    NKTR-255 - Drug Profile 29

    Product Description 29

    Mechanism Of Action 29

    R&D Progress 29

    Recombinant Protein for Metabolic Disorders - Drug Profile 30

    Product Description 30

    Mechanism Of Action 30

    R&D Progress 30

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Dormant Projects 31

    Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Featured News & Press Releases 32

    Oct 28, 2016: Nektar Therapeutics to present data on NKTR-255 at the 2016 Society for Immunotherapy of Cancer Annual Meeting 32

    Apr 27, 2016: Beike Biotechnology Unveils Comprehensive Cancer-treating Immunotherapy Program 32

    Oct 06, 2015: Altor Bioscience Announces NCI Phase II SBIR Grant Award and Publication Supporting Ongoing Clinical Trial of IL-15 Super Agonist ALT-803 in Combination with Anti-CD20 Antibody Therapy for Relapsed / Refractory Non-Hodgkin Lymphoma 32

    Nov 04, 2014: Altor BioScience Initiates Clinical Development of its Novel IL-15 Super Agonist ALT-803 for Relapsed / Refractory Multiple Myeloma Supported by a Newly Awarded Phase II SBIR Grant from NCI 33

    Aug 19, 2014: Altor BioScience Awarded SBIR Phase II Grant by NCI for Clinical Development of its Novel IL-15 Super Agonist for Non-muscle Invasive Bladder Cancer 34

    Aug 15, 2013: Altor BioScience Launches its Proprietary IL-15 Superagonist ALT-803 into Clinical Trials against Cancer 35

    Sep 27, 2012: Altor BioScience Awarded Two SBIR Phase I Grants by NCI for Research on its Novel IL-15 Super Agonists for Hematologic Cancers 36

    Apr 30, 2012: Altor And Melanoma Research Alliance To Co-Support Clinical Studies Of ALT-803 To Treat Metastatic Melanoma 37

    Aug 17, 2011: Altor Receives 5,279 SBIR Phase I Grant For Research On ALT-803 To Treat Bladder Cancer 37

    Jun 28, 2011: Florida Biologix Signs Manufacturing Agreement With Altor BioScience 38

    Appendix 39

    Methodology 39

    Coverage 39

    Secondary Research 39

    Primary Research 39

    Expert Panel Validation 39

    Contact Us 39

    Disclaimer 40

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

42350 | GMDHC0704TDB

Number of Pages

40

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016
Interleukin 12 Receptor (IL12R) - Pipeline Review, H2 2016SummaryGlobal Markets Direct’s, ‘Interleuk...
28 Dec 2016 by Global Markets Direct USD $3,500 More Info
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Pipeline Review, H2 2016
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11....
21 Dec 2016 by Global Markets Direct USD $3,500 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics Inc (Interleukin) is a molecular diagnostics company which develops and ...
14 Nov 2016 by Global Data USD $250 More Info
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016
Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) - Pipeline Review, H2 2016SummaryGlobal M...
09 Nov 2016 by Global Markets Direct USD $3,500 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics, Inc. (Interleukin) is a molecular diagnostics company which develops an...
21 Jul 2016 by Global Data USD $250 More Info
Interleukin Genetics, Inc. (ILIU) - Financial and Strategic SWOT Analysis Review
Interleukin Genetics, Inc. (ILIU) - Financial and Strategic SWOT Analysis Review provides you an in-...
24 May 2016 by Global Data USD $125 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics, Inc. (Interleukin) is a molecular diagnostics company. It develops and ...
02 May 2016 by Global Data USD $250 More Info
CEL-SCI Corporation (formerly Interleukin-2, Inc.) – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryMarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments r...
15 Apr 2016 by Marketline USD $350 More Info
Interleukin Genetics, Inc. – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Project Synopsis:Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and In...
10 Mar 2016 by Marketline USD $350 More Info
Interleukin Genetics, Inc. (ILIU) - Medical Equipment - Deals and Alliances Profile
SummaryInterleukin Genetics, Inc. (Interleukin) is a molecular diagnostics company. It develops and ...
24 Feb 2016 by Global Data USD $250 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Interleukin 15 Receptor Subunit Alpha (CD215 or IL15RA) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Bizwit Research and Consulting
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)
  • VPA Research